Abstract
Purpose: To evaluate the effects of the orally administered thymic protein A on clinical blood parameters and the subjective symptoms common to patients with chronic fatigue and immune dysfunction syndrome (CFIDS). Materials and Methods: A novel immune modulator, thymic protein A, in oral formulation was tested in 23 CFIDS patients manifesting clinical symptoms of CFIDS and abnormal CD8+ subpopulations and interferon pathway-associated enzyme levels. Results: Sixteen of the 23 patients experienced normalization of immune function with a corresponding improvement in clinical symptoms of CFIDS. Conclusion: The data suggest that reinstitution of immune regulation with thymic protein A may ameliorate symptoms associated with CFIDS.